Deflazacort is an oral corticosteroid for people with inflammatory, autoimmune, allergic, or neuromuscular conditions. It helps reduce inflammation and overactive immune responses after conversion to an active metabolite.
Deflazacort is a corticosteroid in the glucocorticoid group. Glucocorticoids mimic some actions of cortisol, a hormone naturally made by the adrenal glands. Deflazacort tablets are oral glucocorticoid corticosteroids used to suppress inflammation and overactive immune responses.
Deflazacort tablets contain Deflazacort, a corticosteroid in the glucocorticoid group. After oral use, Deflazacort is converted to an active metabolite that supports its corticosteroid effects.
After swallowing a tablet, Deflazacort is converted to the active metabolite deflazacort-21-hydroxide. This metabolite enters cells and binds to glucocorticoid receptors. The receptor complex then influences gene activity, reducing production of inflammatory mediators such as cytokines and limiting immune-cell activation.
Cortisol normally helps the body regulate stress, blood pressure, immune responses, and energy use. Deflazacort uses the same receptor system, though at therapeutic doses its glucocorticoid effect is stronger than the body’s day-to-day cortisol signal.
This gene-level action explains why benefits are not always immediate. Symptoms may ease within days for some inflammatory conditions, while immune control in chronic disease can take longer.
Deflazacort 6-beta-OH is another metabolite formed during processing by the liver. Medicines that change liver enzyme activity can alter steroid exposure, which is why interaction checks matter.
Deflazacort is a corticosteroid in the glucocorticoid group. Glucocorticoids mimic some actions of cortisol, a hormone naturally made by the adrenal glands. Their anti-inflammatory potency can reduce swelling, pain, stiffness, skin inflammation, airway inflammation, and immune-driven tissue damage.
Doctors may use Deflazacort in rheumatology for conditions such as rheumatoid arthritis, where immune activity attacks the joints. It is also used in specialist care for Duchenne muscular dystrophy, inflammatory disorders, nephrotic syndrome, severe allergy, some eye inflammatory conditions, and selected autoimmune diseases.
Deflazacort is used in Duchenne muscular dystrophy under specialist neuromuscular supervision. Duchenne muscular dystrophy causes progressive muscle weakness because of changes in the dystrophin gene. Corticosteroids do not correct the genetic cause, yet they can slow functional decline and support longer preservation of walking ability and respiratory function.
A randomised trial comparing Deflazacort, prednisone, and placebo found functional benefit from corticosteroid treatment in boys with Duchenne muscular dystrophy, while adverse-effect patterns differed between treatments [2].
Deflazacort is a prednisolone-derived glucocorticoid. Its anti-inflammatory effects are broadly comparable with prednisolone and prednisone when equivalent anti-inflammatory doses are used, though dose conversion must be handled by the prescriber rather than estimated at home.
| Corticosteroid | Main clinical profile | Relative concerns during longer courses |
|---|---|---|
| Deflazacort | Oral glucocorticoid converted to deflazacort-21-hydroxide | Weight gain, infection, adrenal suppression, bone loss and mood changes remain possible |
| Prednisolone | Widely used oral glucocorticoid | Glucose elevation, appetite change, fluid retention and bone loss can be prominent |
| Prednisone | Prodrug converted to prednisolone | Similar steroid-related metabolic, bone and adrenal effects |
Older comparative reviews found that Deflazacort may have a less unfavourable effect on bone mineral density and glucose metabolism than prednisolone in some patient groups. This does not remove corticosteroid risks. It means the balance of benefit and harm may be more favourable for selected people needing prolonged treatment. A review in Drugs described comparable anti-inflammatory efficacy with differences in metabolic effects across studies [1].
For Duchenne muscular dystrophy, both Deflazacort and prednisone can preserve muscle function for longer than no steroid treatment. The choice often depends on weight trajectory, behaviour, glucose control, bone health, cataract risk, and the person’s response over time.
Deflazacort is not for you if you have a known allergy to Deflazacort or a tablet ingredient. It should also be avoided or used only with specialist direction in untreated systemic infection, including certain fungal infections.
Extra caution is needed with:
This medicine may not be suitable if you have had an allergic reaction to Deflazacort or one of its ingredients. Speak to a clinician before using it if you have an untreated infection, diabetes, fragile bones, eye problems, stomach ulcers or bleeding, liver or heart problems, high blood pressure, seizure disorders, serious mood symptoms, or recent exposure to chickenpox, shingles, or measles. Tell your clinician if you are pregnant or breastfeeding.
Side effects depend on dose, treatment duration, age, underlying condition, and other medicines. Short courses are often tolerated differently from long-term therapy.
Commonly reported steroid-related effects include:
Longer treatment can increase the likelihood of osteoporosis, muscle wasting, cataracts, glaucoma, menstrual changes, delayed wound healing, and adrenal suppression. Some people develop pronounced emotional changes, including low mood, agitation, confusion, mania, or psychotic symptoms. These psychiatric effects can occur even in people without a previous mental health diagnosis.
Seek urgent clinical help for black stools, vomiting blood, severe abdominal pain, sudden visual disturbance, severe confusion, a seizure, facial swelling with breathing difficulty, or signs of serious infection.
One practical detail is easy to miss: steroids can blunt fever and inflammation. A person may feel less unwell than expected despite an infection, so new chills, breathlessness, productive cough, or painful skin redness should not be ignored.
People also sometimes treat every ache during dose reduction as proof that the medicine must be restarted. Withdrawal symptoms, disease activity, and unrelated pain can feel similar. A documented taper plan helps clinicians identify the likely cause.
In clinical practice, doctors often view Deflazacort as a useful steroid option when a patient needs anti-inflammatory or immunosuppressive treatment but has meaningful metabolic or bone-health concerns. It is not a low-risk steroid. It is a different steroid with a different balance of trade-offs.
Prescribers usually focus on the condition being treated, the intended duration, and the person’s existing risks. For rheumatoid arthritis, a corticosteroid may be used as short-term bridging treatment while slower disease-modifying treatment takes effect. For Duchenne muscular dystrophy, the discussion is more often about preserving function over years while monitoring growth, weight, behaviour, eyes, and bones.
A patient who feels well can still develop silent complications such as high blood glucose, raised blood pressure, cataracts, or reduced bone density. Regular review is part of steroid treatment, not an optional extra.
Deflazacort begins affecting glucocorticoid receptors after it is converted to deflazacort-21-hydroxide, though symptom improvement depends on the condition being treated. In inflammatory conditions, pain and swelling may improve within days, while chronic autoimmune control may take longer. The MHRA’s 2025 guidance advises that systemic corticosteroid effects and risks depend on dose and duration, so response should be assessed through planned follow-up rather than a single day’s symptoms.
Deflazacort and prednisolone are both systemic glucocorticoids, and comparisons should use equivalent anti-inflammatory doses rather than tablet-for-tablet assumptions. Deflazacort may have a different metabolic profile, with some studies suggesting less impact on bone and glucose markers in selected groups. A 1995 Drugs review found broadly comparable therapeutic activity across inflammatory conditions, while stressing that adverse effects remain steroid-related.
Deflazacort can cause these effects. Increased appetite, fluid retention, altered fat distribution, and reduced activity during illness can all contribute to weight gain. The risk rises with longer courses and higher steroid exposure. The EMA’s 2024 safety information identifies metabolic effects as a recognised class issue for systemic corticosteroids, so unexplained rapid weight increase or swelling should be raised during treatment review.
Regular corticosteroid treatment can suppress natural cortisol secretion by the adrenal glands. A taper gives the adrenal system time to recover and reduces the risk of adrenal insufficiency, which can cause severe fatigue, dizziness, vomiting, and low blood pressure. UK perioperative guidance published by the UK Clinical Pharmacy Association in 2025 highlights the clinical significance of adrenal suppression during illness and surgery [4].
Yes. Insomnia, irritability, anxiety, low mood, agitation, and more severe psychiatric reactions can occur with systemic corticosteroids. Symptoms may appear early, after a dose change, or during longer treatment. WHO safety information from 2023 includes mental and behavioural effects among clinically relevant concerns when systemic medicines alter hormonal and immune pathways.
Deflazacort can be used to reduce inflammation in rheumatoid arthritis, usually as part of a broader treatment plan directed by rheumatology. It can ease pain and stiffness while longer-acting disease-modifying treatment is being started or adjusted. Steroids control inflammation but do not replace treatments designed to limit long-term joint damage. NICE guidance updated in 2025 supports combining symptom control with disease-modifying treatment and rheumatology follow-up.
Your order will be securely packed and shipped within 24 hours. This is exactly what your package will look like (images of an actual item sent). It has the size and look of a regular private letter (24x11x0.7 cm) and its contents cannot be seen.
Long-term Deflazacort treatment can maintain control of inflammatory disease or support function in selected neuromuscular conditions. The trade-off is cumulative corticosteroid exposure. The lowest dose that maintains disease control is usually preferred, with regular review of whether the dose still matches the clinical need.
Monitoring may include blood pressure, weight, blood glucose, eye symptoms, bone health, growth in children, and infection history. People with diabetes may need more frequent glucose checks because steroids can raise blood sugar even when diabetes had previously been stable. Clinicians may also review interacting medicines. They can adjust monitoring when treatment risks change. Follow-up frequency depends on dose, duration, and individual risk.
Vaccination planning also matters. Live vaccines may be unsuitable during immunosuppressive corticosteroid treatment, while non-live vaccines can still be clinically useful. The WHO recognises systemic corticosteroid use as a factor that can alter immune responses to vaccination [3].
